BOTHELL, Wash.--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company discovering new drug therapies for eye diseases, today presented preclinical data from a study of a blinding eye disease called retinopathy of prematurity (ROP) demonstrating an improvement in retinal abnormalities following treatment with the company’s visual cycle modulation compound. These data were presented today by James D. Akula, Ph.D., Instructor of Ophthalmology at Harvard Medical School at Children’s Hospital Boston at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida.
